Diamandis Eleftherios P, Borgoño Carla A, Scorilas Andreas, Yousef George M, Harbeck Nadia, Dorn Julia, Schmalfeldt Barbara, Schmitt Manfred
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada.
Tumour Biol. 2003 Nov-Dec;24(6):299-309. doi: 10.1159/000076462.
Human kallikrein 5 (hK5; encoded by the KLK5 gene) is a secreted serine protease expressed in hormonally regulated tissues, including the breast and ovary. We have previously reported regulation of the KLK5 gene by estrogens and progestins and its clinical value as a marker of poor prognosis in breast and ovarian cancers. We thus hypothesized that hK5 may represent a potential biomarker for ovarian carcinomas, at the protein level. Using a newly developed ELISA, hK5 levels were quantified (nanograms per milligram of total protein) in 22 low malignant potential (LMP) and 132 epithelial ovarian tumors and correlated with various clinicopathological variables and outcome [progression-free survival (PFS), overall survival (OS)]. hK5 concentration in LMP tumors ranged from 0 to 2.3 ng/mg (mean = 0.24) and from 0 to 220 ng/mg (mean = 3.35) in ovarian tumor cytosols (p = 0.002). Using a cutoff value of 0.15 ng/mg, 60% of ovarian tumors were categorized as hK5 positive. We found a strong correlation between patients with hK5-positive tumors and disease stages III/IV and grade 3 tumors (all p < 0.05). Univariate survival analysis revealed that hK5-positive patients had a significantly shorter PFS and OS (p < 0.05). Kaplan-Meier survival curves further confirmed an increased risk of relapse and death in women with hK5-positive tumors (p = 0.015 and p = 0.019, respectively). Multivariate analysis indicated that the prognostic value of hK5 was not independent from other parameters in the entire group of patients. When stratified by tumor grade (G1/2 vs. G3) and debulking success (optimal vs. suboptimal), univariate and multivariate analyses demonstrated that hK5 was an independent indicator of poor prognosis for patients with grade 3 tumors and with optimal debulking (p < 0.05). In patients with disease stage I/II versus III/IV, hK5 positivity was independently associated with a shorter PFS (p = 0.046) and marginally decreased OS (p = 0.08), in multivariate analysis. Lastly, we observed a fairly weak, positive, but statistically significant correlation between the expression levels of tissue hK5 and tissue CA125 (r(s) = 0.297; p < 0.001). Our findings provide evidence for an association between hK5 and more aggressive forms of epithelial ovarian cancer.
人组织激肽释放酶5(hK5;由KLK5基因编码)是一种分泌型丝氨酸蛋白酶,在包括乳腺和卵巢在内的受激素调节的组织中表达。我们之前曾报道过雌激素和孕激素对KLK5基因的调控及其作为乳腺癌和卵巢癌预后不良标志物的临床价值。因此,我们推测hK5在蛋白质水平上可能是卵巢癌的潜在生物标志物。使用新开发的酶联免疫吸附测定法(ELISA),对22例低恶性潜能(LMP)肿瘤和132例上皮性卵巢肿瘤中的hK5水平(每毫克总蛋白中的纳克数)进行了定量,并将其与各种临床病理变量及预后[无进展生存期(PFS)、总生存期(OS)]相关联。LMP肿瘤中hK5浓度范围为0至2.3纳克/毫克(平均值 = 0.24),卵巢肿瘤细胞溶质中hK5浓度范围为0至220纳克/毫克(平均值 = 3.35)(p = 0.002)。使用0.15纳克/毫克的临界值,60%的卵巢肿瘤被归类为hK5阳性。我们发现hK5阳性肿瘤患者与疾病III/IV期及3级肿瘤之间存在强相关性(所有p < 0.05)。单因素生存分析显示,hK5阳性患者的PFS和OS显著缩短(p < 0.05)。Kaplan-Meier生存曲线进一步证实,hK5阳性肿瘤女性复发和死亡风险增加(分别为p = 0.015和p = 0.019)。多因素分析表明,在整个患者组中,hK5的预后价值并非独立于其他参数。当按肿瘤分级(G1/2与G3)和减瘤成功情况(最佳与次优)分层时,单因素和多因素分析均表明,hK5是3级肿瘤且减瘤最佳患者预后不良的独立指标(p < 0.05)。在疾病I/II期与III/IV期患者中,多因素分析显示,hK5阳性与较短的PFS独立相关(p = 0.046)且总生存期略有降低(p = 0.08)。最后,我们观察到组织hK5表达水平与组织CA125之间存在相当弱的正相关,但具有统计学意义(r(s) = 0.297;p < 0.001)。我们的研究结果为hK5与更具侵袭性的上皮性卵巢癌形式之间的关联提供了证据。